SOUTH SAN FRANCISCO, Calif., March 7, 2017/PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, announced today that Titan President and CEO Sunil Bhonsle will present at the 29th annual ROTH Conference on Monday, March 13 at 3:30 p.m. at The Ritz-Carlton in Laguna Niguel, Calif.
Mr. Bhonsle will review the company's ongoing ProNeura-based product development programs and also provide an update on Probuphine®, which was approved by the U.S. Food and Drug Administration in May 2016 for the maintenance treatment of opioid addiction. The presentation will be available as a live and archived webcast at http://wsw.com/webcast/roth31/ttnp. The replay will be available for 90 days following the live broadcast. Interested parties may also access the webcast from the Titan website at www.titanpharm.com.